acute myeloid leukemia

[Cancer Discovery] The authors presented a humanized animal model of myelofibrosis patient-derived xenografts which were robustly engrafted patient cells that recapitulated the patient's genetic hierarchy and pathologies such as reticulin fibrosis and propagation of myeloproliferative neoplasms-initiating stem cells.

[Scientific Reports] In line with a predominantly microenvironment-mediated activity of daratumumab in acute myeloid leukemia (AML), CD38 inhibition significantly induced antibody-dependent phagocytosis and showed interference with AML cell trafficking in vivo in a xenograft transplantation model, but overall lacked robust anti-leukemic effects.

[Nature Communications] Researchers indicated that relapse can originate from therapy-resistant mature acute myeloid leukemia cells, and suggested differentiation therapy combined with targeted eradication of mature leukemia-derived lineages may improve disease outcome.

[Biosight Ltd. (GlobeNewswire, Inc.)] Biosight Ltd.,announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

[International Journal of Cancer] Investigators introduced a CD33-directed third-generation CAR T cell product for the treatment of patients with acute myeloid leukemia.

[Journal of Experimental & Clinical Cancer Research] Gain or loss of functional leukemia cell models were produced, and in vitro and in vivo experiments were applied to demonstrate its leukemogenic phenotypes.